Unknown

Dataset Information

Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.


ABSTRACT: Thymic epithelial tumors (TETs) are rare thoracic cancers that are broadly classified as thymomas and thymic carcinomas. Surgery is the cornerstone of management for early-stage disease. There are a limited number of effective treatment options for patients with advanced or recurrent disease. The occurrence of paraneoplastic autoimmune disorders in patients with TETs, especially thymomas, creates significant challenges for the development of immunotherapy, including immune checkpoint inhibitors, as a feasible treatment option. In addition, patients with TETs are at increased risk for the development of immune-mediated toxicity with a predilection for musculoskeletal and neuromuscular adverse events upon treatment with immunotherapy. The identification of biomarkers of response and toxicity

SUBMITTER: Ballman M 

PROVIDER: S-EPMC9105984 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature